Home
Markets
Charts & Ideas
Algo
News
Store
Brokers
Download
Economic Calendar
Trading Signals
WebTerminal
Heatmap
Type
/
to search: @user, $symbol
Search
Log in
Create an account
English
Русский
中文
Español
Português
日本語
Deutsch
한국어
Français
Italiano
Türkçe
VKTX
#1557
Viking Therapeutics, Inc. - Common Stock
32.1
6
USD
-0.05%
Market Price
Sector:
Healthcare
Base:
USD
Profit Currency:
USD
Daily Range
Year Range
Daily Change
-5.02%
Monthly Change
-4.06%
6 month change
-2.49%
Year Change
+19.24%
Previous Close
33.8
6
Open
32.1
6
Low
32.1
6
High
32.1
6
Volume
128
Markets
US Stock Market
Healthcare
Biotechnology
VKTX
1D
1W
1M
3M
6M
YTD
1Y
5Y
Open full chart
Financials
Overview
Statement
Statistics
Documents
Quarterly
Annual
Value
2020
2021
2022
2023
2024
2025
Current
Key stats
Total common shares outstanding
74.13 M
78.36 M
78.42 M
100.49 M
112.25 M
115.55 M
116.65 M
Valuation ratios
Enterprise value
388.25 M
334.1 M
631.49 M
1.78 B
4.49 B
3.9 B
3.84 B
Price to earnings ratio
10.35
6.46
-9.47
-20.09
-39.84
-11.03
-7.27
Price to sales ratio
—
—
—
—
—
—
—
Price to cash flow ratio
18.77
7.46
-13.53
-23.5
-49.98
-14.22
-9.29
Price to book ratio
1.67
1.76
4.5
4.95
4.98
6.2
1.71
Enterprise value to EBITDA ratio
—
—
—
-16.34
-26.7
-9.68
—
Profitability ratios
Return on assets %
-0.15
-0.26
-0.41
-0.23
-0.12
-0.5
-0.25
Return on equity %
-0.16
-0.27
-0.47
-0.25
-0.12
-0.56
-0.31
Return on invested capital %
-11.89 K
-49.99 K
-28.77 K
-23.85 K
-37.93 K
-587.08 K
-11.8 K
Gross margin %
—
—
—
—
—
—
—
Operating margin %
—
—
—
—
—
—
—
EBITDA margin %
—
—
—
—
—
—
—
Net margin %
—
—
—
—
—
—
—
Liquidity ratios
Quick ratio
—
—
—
—
—
—
—
Current ratio
21.12
23.98
7.61
19.19
33.09
9.33
4.72
Inventory turnover
—
—
—
—
—
—
—
Asset turnover
0
0
0
0
0
0
0
Solvency ratios
Debt to assets ratio
—
—
—
—
—
—
—
Debt to equity ratio
—
—
—
—
—
—
—
Long term debt to total assets ratio
—
—
—
—
—
—
—
Long term debt to total equity ratio
—
—
—
—
—
—
—
Per share metrics
Operating cash flow per share
-0.3
-0.62
-0.63
-0.78
-0.81
-2.47
-3.66
EBIT per share
-0.59
-0.72
-0.92
-1.07
-1.38
-3.49
-4.9
EBITDA per share
—
—
—
-1.16
-1.54
-3.57
-4.95
Total debt per share
—
—
—
—
—
—
—
Cash per share
3.42
2.62
2.02
3.84
8.28
6.26
4.31
Net current asset value per share
3.53
2.73
2.17
3.89
8.32
6.35
4.45
Tangible book value per share
3.37
2.62
1.89
3.69
8.07
5.67
3.51
Working capital per share
3.36
2.61
1.89
3.69
8.07
5.67
3.51
Book value per share
3.37
2.62
1.89
3.69
8.07
5.67
3.51
News
Why Is Viking Therapeutics (VKTX) Up 2.3% Since Last Earnings Report?
Can Awiqli Help Novo Nordisk Build a New Growth Engine Beyond GLP-1s?
How Does LLY's Q2 GLP-1 Portfolio Performance Stack Up Against NVO's?
LLY Up Around 6% Post Robust Q2 Results: Buy, Sell or Hold the Stock?
Can Novo Nordisk's GLP-1 Pill Momentum Offset LLY's Growing Edge?
LLY's Foundayo Posts $98M in Q2 Sales: What's Next for the Oral GLP-1?
Novo Nordisk Dips 4% in a Month: How Should Investors Play the Stock?
3 Best Stocks With 100%+ Upside to Buy This Week, According to Analysts - TipRanks.com
Novo Nordisk Before Q2 Earnings: How Should Investors Play the Stock?
VKTX Q2 Earnings Beat Estimates Despite Surge in R&D Costs
Viking Therapeutics, Inc. (VKTX) Q2 2026 Earnings Call Transcript
How Will Ozempic and Wegovy Sales Aid NVO's Upcoming Q2 Results?